Open-label trial and randomized, double-blind, placebo-controlled, crossover trial of hydrogen-enriched water for mitochondrial and inflammatory myopathies.
Ito M, Ibi T, Sahashi K, Ichihara M, Ito M, Ohno K · Medical gas research · 2011
Research-use notice
Independent study record
Each H2HUBB study page organizes source-linked research details for educational use. Interpretation should remain proportional to the study design, population, controls, and limitations.
The publication “Open-label trial and randomized, double-blind, placebo-controlled, crossover trial of hydrogen-enriched water for mitochondrial and inflammatory myopathies.” is organized in H2HUBB under the research focus molecular hydrogen diabetes metabolic study 2011 ito. The publication is cited as Ito M, Ibi T, Sahashi K, Ichihara M, Ito M, Ohno K, Medical gas research, 2011. This randomized controlled trial examined Open-label trial and randomized, double-blind, placebo-controlled, crossover trial of hydrogen-enriched water for mitochondrial and inflammatory myopathies. The abstract describes Human participants; sample size 10; reported duration 12 weeks. The abstract reports: Hydrogen-enriched water improves mitochondrial dysfunction in MM and inflammatory processes in PM/DM. Less prominent effects with the double-blind trial compared to the open-label trial…. This is an automated editorial draft based on the abstract and requires source review before publication.
Molecular hydrogen diabetes metabolic study 2011 ito overview
Molecular hydrogen has prominent effects on more than 30 animal models especially of oxidative stress-mediated diseases and inflammatory diseases. In addition, hydrogen effects on… Because this is human clinical evidence, relevance depends on participant selection, controls, sample size, treatment duration, adherence, outcome measures, and replication.
Study design and hydrogen intervention
Publication type: Randomized controlled trial. Evidence type: Human clinical evidence. Research model or population: Human participants. Sample size: 10. Randomized: Yes. Blinding: Double-blind. Control status: Placebo-controlled.
Delivery method: Other or not reported. Treatment duration: 12 weeks.
Reported findings and scientific interpretation
For this molecular hydrogen diabetes metabolic study 2011 ito, the study record reports the following: The abstract reports: Hydrogen-enriched water improves mitochondrial dysfunction in MM and inflammatory processes in PM/DM. Less prominent effects with the double-blind trial compared to the open-label trial…
These findings should be interpreted as one piece of evidence rather than as a stand-alone medical conclusion. Results can be influenced by the research model, study design, treatment protocol, sample size, outcome selection, statistical methods, and whether the findings have been independently reproduced.
How this research record was prepared
H2HUBB organizes bibliographic details, study design information, intervention data, outcomes, limitations, and safety notes from the available scientific source. Automated classification supports database organization, but it does not replace critical reading of the complete paper. Source identifiers, evidence labels, and delivery-method fields are retained so readers can verify the record and compare it with related publications. A missing field means the information was unavailable or not reported in the structured source; it should not be treated as a negative finding.
Limitations, safety, and original source
Limitations: The reported sample size was small.
Safety: No adverse effect was observed in either trial except for hypoglycemic episodes in an insulin-treated MELAS patient, which subsided by reducing the insulin dose.
This H2HUBB page is an educational research record, not medical advice. Review the original scientific source for the complete methods and results. Continue exploring the H2HUBB Molecular Hydrogen Research Library to compare evidence types, delivery methods, and related topics.